|
|
|
MIRA INFORM REPORT
|
Report No. : |
484491 |
|
Report Date : |
11.01.2018 |
IDENTIFICATION DETAILS
|
Name : |
HYGEIA PHARMACEUTICALS |
|
|
|
|
Registered Office : |
Plot No. 295, Industrial Triangle, Kahuta Road, Islamabad |
|
|
|
|
Country : |
Pakistan |
|
|
|
|
Date of Incorporation : |
May, 2011 |
|
|
|
|
Legal Form : |
Partnership business |
|
|
|
|
Line of Business : |
Subject is engaged in import, manufacture & marketing of
Pharmaceutical Products. |
|
|
|
|
No. of Employees : |
33 |
RATING & COMMENTS
(Mira Inform has adopted New Rating mechanism w.e.f. 23rd
January 2017)
|
MIRA’s Rating : |
A |
|
Credit Rating |
Explanation |
Rating Comments |
|
A |
Acceptable Risk |
Business dealings permissible with
moderate risk of default |
|
Status : |
Satisfactory |
|
|
|
|
Payment Behaviour : |
Slow and delayed |
|
|
|
|
Litigation : |
Clear |
NOTES :
Any query related to this report can be made
on e-mail : infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List
|
Country Name |
Previous Rating (30.06.2017) |
Current Rating (30.09.2017) |
|
Pakistan |
B1 |
B1 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low Risk |
A2 |
|
Moderately Low Risk |
B1 |
|
Moderate Risk |
B2 |
|
Moderately High Risk |
C1 |
|
High Risk |
C2 |
|
Very High Risk |
D |
PAKISTAN - ECONOMIC
OVERVIEW
Decades of internal political disputes and low levels of foreign investment have led to slow growth and underdevelopment in Pakistan. Pakistan has a large English-speaking population. Nevertheless, a challenging security environment, electricity shortages, and a burdensome investment climate have deterred investors. Agriculture accounts for one-fifth of output and two-fifths of employment. Textiles and apparel account for most of Pakistan's export earnings; Pakistan's failure to diversify its exports has left the country vulnerable to shifts in world demand. Pakistan’s GDP growth has gradually increased since 2012. Official unemployment was 6.1% in 2016, but this fails to capture the true picture, because much of the economy is informal and underemployment remains high. Human development continues to lag behind most of the region.
In 2013, Pakistan embarked on a $6.3 billion IMF Extended Fund Facility, which focused on reducing energy shortages, stabilizing public finances, increasing revenue collection, and improving its balance of payments position. The program concluded in September 2016. Although Pakistan missed several structural reform criteria, it restored macroeconomic stability, improved its credit rating, and boosted growth. The Pakistani rupee, after heavy depreciation in 2013, remained relatively stable against the US dollar in 2016. Low global oil prices in 2016 contributed to a narrowing current account deficit and lower inflation. Remittances from overseas workers continued to be a key revenue source, also mitigating the impact of the lack of foreign investment and a growing trade deficit on the country’s current account.
Pakistan must continue to address several longstanding issues, including expanding investment in education and healthcare, adapting to the effects of climate change and natural disasters, improving the country’s business environment, reducing dependence on foreign donors, and widening the country’s tax base. Given demographic challenges, Pakistan’s leadership will be pressed to implement economic reforms, promote further development of the energy sector, and attract foreign investment to support sufficient economic growth necessary to employ its growing and rapidly urbanizing population, much of which is under the age of 25.
In an effort to boost development, Pakistan and China are implementing the “China-Pakistan Economic Corridor,” a $46 billion investment program targeted towards the energy sector and other infrastructure projects that Islamabad and Beijing had agreed on in early 2013.
|
Source
: CIA |
Company
Name
HYGEIA PHARMACEUTICALS
Full
Address
|
Registered
Address |
|
Plot No. 295, Industrial
Triangle, Kahuta Road, Islamabad, Pakistan |
|
Tel # |
92 (51) 4490882, 4490983 |
|
Fax # |
92 (51) 4490983 |
Short
Description Of Business
|
a. |
Nature of Business |
Import, Manufacture & Marketing
of Pharmaceutical Products |
|
b. |
Year Established |
May, 2011 |
Branches
|
None |
Legal
Status
|
Subject Company was established as a Partnership business in May, 2011 |
Details
of Management
|
Names |
Nationality |
Address |
Occupation |
Designation |
|
Mr. Raja
Farrukh Javed Dr. Abdullah Qureshi |
Pakistani Pakistani |
Plot No. 295, Industrial Triangle, Kahuta Road, Islamabad Plot No. 295, Industrial Triangle, Kahuta Road, Islamabad |
Business Business |
CEO / Managing Partner Partner |
Associated
Companies
|
(1) Technovision Pharmaceuticals,
Pakistan. (2) Horizon Pharma, Pakistan. |
Business
Activities
Subject Company is engaged in import, manufacture & marketing of Pharmaceutical Products.
Local sales are mostly done with cash term basis to its domestic
customers.
Subject import globally from
Companies belongs to European
Countries, Korea, India & China.
Its major customers are Private Hospital, Pharmacies deal with
cash term basis.
Subject operates from owned office premises situated at industrial
area of Islamabad.
Subject employs about 33 persons in its set up.
Annual
Production Volume
|
The
capacity and production of the Company’s plant is indeterminable as it is
multi- products and involves various process of manufacturing |
Annual
Sales Volume
|
Year |
In Pak Rupees |
|
2016 |
24,000,000/- (Estimated) |
Trade
Suppliers (Foreign)
|
Subject import globally from
Companies belongs to European Countries, Korea, India & China. Its global
trade suppliers are Companies related to Pharmaceutical Raw Materials |
Bankers
|
(1) Silk Bank Limited,
Pakistan. (2) Habib Bank Limited,
Pakistan. (3) Faysal Bank
Limited, Pakistan. (4) Bank
Alfalah Limited, Pakistan. |
Comments
Subject Company was established
in 2011 and is engaged in import, manufacture & marketing of Pharmaceutical
Products. Trade relations are reported as fair. In view of current disturbed
economic and political situation, we would advise to deal with all the business
in Pakistan with some caution.
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
INR 63.83 |
|
|
1 |
INR 86.28 |
|
Euro |
1 |
INR 76.13 |
|
PKR |
1 |
INR 0.58 |
Note :
Above are approximate rates obtained from sources believed to be correct
INFORMATION DETAILS
|
Analysis Done by
: |
NIS |
|
|
|
|
Report Prepared
by : |
TRU |
RATING EXPLANATIONS
|
Credit Rating |
Explanation |
Rating Comments |
|
A++ |
Minimum Risk |
Business dealings permissible with minimum
risk of default |
|
A+ |
Low Risk |
Business dealings permissible with low risk
of default |
|
A |
Acceptable Risk |
Business dealings permissible with
moderate risk of default |
|
B |
Medium Risk |
Business dealings permissible on a regular
monitoring basis |
|
C |
Medium High Risk |
Business dealings permissible preferably on
secured basis |
|
D |
High Risk |
Business dealing not recommended or on
secured terms only |
|
NB |
New Business |
No recommendation can be done due to
business in infancy stage |
|
NT |
No Trace |
No recommendation can be done as the business
is not traceable |
NB is stated where there is insufficient information to facilitate rating. However, it is not to be considered as unfavourable.
This score serves as a reference to assess
SC’s credit risk and to set the amount of credit to be extended. It is
calculated from a composite of weighted scores obtained from each of the major
sections of this report. The assessed factors are as follows:
·
Financial
condition covering various ratios
·
Company
background and operations size
·
Promoters
/ Management background
·
Payment
record
·
Litigation
against the subject
·
Industry
scenario / competitor analysis
·
Supplier
/ Customer / Banker review (wherever available)
This report is issued at
your request without any risk and responsibility on the part of MIRA INFORM
PRIVATE LIMITED (MIPL) or its officials.